CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 540 target
Drug / intervention
LY3537982 +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04956640
NCT04956640Phase 2ActiveHigh Momentum
CompareCT.gov

A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors

Eli Lilly and Company·interventional·Posted Jul 9, 2021·Updated May 29, 2026

In Brief

A Phase 2 clinical trial evaluating LY3537982, Pembrolizumab, and 4 other interventions for Carcinoma, Non-Small-Cell Lung and 5 related conditions. Active but no longer recruiting, targeting 540 participants across 49 sites in 6 countries.

Signals

Enrolling ahead of pace

Detailed Summary

The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Biliary Tract Neoplasms
CountriesAustralia, Canada, France, Japan, South Korea, United States
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 2Active
202220232024202520262027
First PostedJul 9, 2021
Enrollment StartJul 19, 2021
Primary CompletionApr 1, 2027
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 5.0 years agoPrimary completion in 9 months

Interventions

LY3537982drug

Oral

Pembrolizumabdrug

Intravenous

Cetuximabdrug

Intravenous

Pemetrexeddrug

Intravenous

Cisplatindrug

Intravenous

Carboplatindrug

Intravenous